Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan-Feb;54(1):46-50.
doi: 10.4103/ijp.IJP_384_20.

Neuroprotective effects of linagliptin in a rotenone-induced rat model of Parkinson's disease

Kinjal V Abhangi  1 , Jigneshkumar Ishwarlal Patel  1
Affiliations

Neuroprotective effects of linagliptin in a rotenone-induced rat model of Parkinson's disease

Kinjal V Abhangi et al. Indian J Pharmacol. 2022 Jan-Feb.

Abstract

The present study investigates the antiParkinsonian activity of dipeptidyl peptidase-4 (DPP-IV) inhibitor, linagliptin. The experimental Parkinson's disease (PD) was induced by administration of rotenone at a dose of 1.5 mg/kg at alternate day subcutaneously for 21 days. Standard drug (levodopa-200 mg/kg and carbidopa-50 mg/kg) and treatment drug (linagliptin-5 mg/kg, 10 mg/kg, and 20mg/kg) were administered orally daily 1 h before rotenone administration. In a rat rotenone model, linagliptin improved muscle coordination, motor performance, and corrected akinesia. Pretreatment with linagliptin showed significant higher levels of superoxide dismutase, catalase, and glutathione in brain homogenate of animals. Linagliptin significantly elevated the levels of striatal DA and active glucagon-like peptide 1 in brain homogenate of animals. Furthermore, linagliptin amended alterations induced by rotenone in the thiobarbituric acid reactive substances and inflammatory marker such as tumor necrosis factor-α level. The results of the present study indicate the neuroprotective potential of linagliptin for the management of PD might be due to remarkable improvement in motor functions, antioxidant, anti-inflammatory, anti-apoptotic, and neuroprotective mechanisms.

Keywords: Dipeptidyl peptidase-4 inhibitors; Parkinson's disease; glucagon-like peptide 1; linagliptin; rotenone.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Effect of linagliptin on rotenone-induced alterations in striatal DA level in brain homogenate
Figure 2
Figure 2
Effect of linagliptin on rotenone-induced alterations in active glucagon-like peptide-1 level in brain homogenate
Figure 3
Figure 3
Effect of linagliptin on rotenone-induced alterations in tumor necrosis factor-alpha level in brain homogenate
See this image and copyright information in PMC

References

    1. Montie HL, Durcan TM. The cell and molecular biology of neurodegenerative diseases: An overview. Front Neurol. 2013;4:194. - PMC - PubMed
    1. Badawi GA, Abd El Fattah MA, Zaki HF, El Sayed MI. Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease. Inflammopharmacology. 2017;25:369–82. - PubMed
    1. Huang Z, Fuente-Fernández Rd, Stoessl AJ. Etiology of Parkinson's disease. Can J Neurol Sci. 2003;30(Suppl 1):S10–8. - PubMed
    1. Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: Theoretical and practical applications. Curr Med Res Opin. 2011;27:547–58. - PubMed
    1. Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: Mechanisms of action. Drug Discov Today. 2016;21:802–18. - PubMed